Percent of patients with SD ≥6 months/PR/CR^{a} | |||||
---|---|---|---|---|---|

Univariable | Multivariable | ||||

Parameters | Percentage | Wald | P | Wald | P |

Matched | 7.78 | 0.005 | 5.41 | 0.020 | |

Yes (n = 87) | 34.5% | ||||

No (n = 93) | 16.1% | ||||

Breast | 3.28 | 0.070 | 0.643 | 0.423 | |

Yes (n = 60) | 33.3% | ||||

No (n = 120) | 20.8% | ||||

Brain | 0.217 | 0.642 | N/A | N/A | |

Yes (n = 15) | 20% | ||||

No (n = 165) | 25.5% | ||||

Gastrointestinal | 0.106 | 0.744 | N/A | N/A | |

Yes (n = 35) | 23% | ||||

No (n = 145) | 25.5% | ||||

Genitourinary | 0.069 | 0.793 | N/A | N/A | |

Yes (n = 22) | 23% | ||||

No (n = 158) | 25.3% | ||||

Head and neck | 1.38 | 0.241 | N/A | N/A | |

Yes (n = 16) | 12.5% | ||||

No (n = 164) | 26.2% | ||||

Lung | 0.363 | 0.547 | N/A | N/A | |

Yes (n = 16) | 31% | ||||

No (n = 164) | 24.4% | ||||

Skin/melanoma | 0.287 | 0.592 | N/A | N/A | |

Yes (n = 11) | 18% | ||||

No (n = 169) | 25.4% | ||||

Metastasis at time of biopsy | 0.371 | 0.542 | N/A | N/A | |

Yes (n = 138) | 26% | ||||

No (n = 42) | 21% | ||||

Therapy was 1st line | 0.820 | 0.365 | N/A | N/A | |

Yes (n = 43) | 30% | ||||

No (n = 137) | 23.4% | ||||

Single agent (n = 95) | 24% | 0.067 | 0.796 | N/A | N/A |

Combination (n = 85) | 26% | ||||

PFS (PFS2)^{b} | |||||

Univariable | Multivariable | ||||

Parameters | Median (months, 95%CI) | χ^{2} | P | Wald | P |

Matched | 3.65 | 0.056 | 2.35 | 0.039 | |

Yes (n = 87) | 4.0 (3.1–4.9) | ||||

No (n = 93) | 3.0 (2.5–3.5) | ||||

Breast | 2.20 | 0.138 | NA | NA | |

Yes (n = 60) | 4.0 (3.2–4.8) | ||||

No (n = 120) | 3.0 (2.4–3.8) | ||||

Brain | 0.001 | 0.982 | NA | NA | |

Yes (n = 15) | 4.0 (3.1–4.9) | ||||

No (n = 165) | 3.4 (2.9–3.9) | ||||

Gastrointestinal | 1.06 | 0.304 | NA | NA | |

Yes (n = 35) | 2.8 (2.2–3.4) | ||||

No (n = 145) | 3.6 (3.0–4.2) | ||||

Genitourinary | 0.02 | 0.893 | NA | NA | |

Yes (n = 22) | 3.4 (2.5–4.3) | ||||

No (n = 158) | 3.4 (2.9–3.9) | ||||

Head and neck | 0.83 | 0.363 | NA | NA | |

Yes (n = 16) | 2.2 (0.9–3.5) | ||||

No (n = 164) | 3.6 (3.2–4.0) | ||||

Lung | 0.07 | 0.791 | NA | NA | |

Yes (n = 16) | 3.0 (0.0–7.7) | ||||

No (n = 164) | 3.4 (3.0–3.8) | ||||

Skin/melanoma | 0.26 | 0.610 | NA | NA | |

Yes (n = 11) | 7.7 (1.6–13.8) | ||||

No (n = 169) | 3.4 (3.0–3.8) | ||||

Metastasis at time of biopsy | 0.02 | 0.897 | NA | NA | |

Yes (n = 138) | 3.4 (3.0–3.9) | ||||

No (n = 42) | 4.0 (3.0–5.0) | ||||

Therapy was 1st line | 2.3 | 0.127 | 3.0 | 0.083 | |

Yes (n = 43) | 4.5 (3.7–5.3) | ||||

No (n = 137) | 3.0 (2.5–3.5) | ||||

Single agent (n = 95) | 4.0 (3.3–4.7) | 0.648 | 0.421 | NA | NA |

Combination (n = 85) | 3.4 (2.8–4.0) |

↵

^{a}*P*values were computed using binary logistic regression analysis (univariable and multivariable); variables with*P*< 0.1 in univariable analysis were included in the multivariable model. The*P*value was 0.012 for “matched vs. unmatched” with the inverse propensity score weighting method. When the propensity score was added as a covariate (propensity adjustment),*P*= 0.017. The Wald test is a way of testing the significance of variables in a statistical model; the higher the Wald, the higher the association in the model.↵

^{b}*P*values were computed using the Kaplan–Meier method (log-rank test for univariable and Cox regression for multivariate analysis); variables with*P*< 0.2 in univariable analysis were included in the Cox regression model (multivariable, backward conditional method). The χ^{2}and Wald values test the significance of variables in the statistical model; the higher the χ^{2}or Wald, the higher the association in the model. When the propensity score was added as a covariate with “matched vs. not,” the*P*value for “matched vs. not” was 0.140.